Mesalazine Other names: Mesalamine Mesalazine 5-aminosalicylic acid 5-ASA

Chemical formula: C₇H₇NO₃ Molecular mass: 153.135 g/mol PubChem compound: 4075

Therapeutic indications

Mesalazine is indicated for:

Mild to moderate active ulcerative colitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

For the induction of clinical and endoscopic remission in patients with mild to moderate, active ulcerative colitis.

For maintenance of remission.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 g daily for 2-4 weeks and 1-2 g daily thereafter

2-4 g or 1.2-4.8 g once daily depending on pharmaceutical form

30-50 mg/kg/day and thereafter 15-30 mg/kg/day in divided doses

Crohn's disease

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

For the maintenance of surgically-induced remission of Crohn’s Disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2.4 g per day

30-50 mg/kg/day and thereafter 15-30 mg/kg/day in divided doses

Contraindications

Mesalazine is contraindicated in the following cases:

Severe hepatic impairment

Hepatic failure stage IV

Severe renal impairment (GFR <30ml/min/1.73m²)

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

Mesalazine Other names: Mesalamine Mesalazine 5-aminosalicylic acid 5-ASA

Therapeutic indications

Mild to moderate active ulcerative colitis

2 g daily for 2-4 weeks and 1-2 g daily thereafter

2-4 g or 1.2-4.8 g once daily depending on pharmaceutical form

30-50 mg/kg/day and thereafter 15-30 mg/kg/day in divided doses

Crohn's disease

2.4 g per day

30-50 mg/kg/day and thereafter 15-30 mg/kg/day in divided doses

Contraindications

Severe hepatic impairment

Severe renal impairment (GFR <30ml/min/1.73m²)

Get recommendations

Related medicines